Taysha Gene Therapies Inc (NASDAQ:TSHA) has a beta value of 0.93 and has seen 3.13 million shares traded in the last trading session. The company, currently valued at $385.29M, closed the last trade at $1.88 per share which meant it lost -$0.17 on the day or -8.29% during that session. The TSHA stock price is -129.79% off its 52-week high price of $4.32 and 36.7% above the 52-week low of $1.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.2 million shares traded. The 3-month trading volume is 4.34 million shares.
The consensus among analysts is that Taysha Gene Therapies Inc (TSHA) is Buy stock at the moment, with a recommendation rating of 1.09. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Sporting -8.29% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TSHA stock price touched $1.88 or saw a rise of 9.18%. Year-to-date, Taysha Gene Therapies Inc shares have moved 8.67%, while the 5-day performance has seen it change 8.67%. Over the past 30 days, the shares of Taysha Gene Therapies Inc (NASDAQ:TSHA) have changed -21.01%. Short interest in the company has seen 21.88 million shares shorted with days to cover at 3.66.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 62.4% from current levels. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is -165.96% off the targeted high while a plunge would see the stock gain -165.96% from current levels.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Figures show that Taysha Gene Therapies Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -16.07% over the past 6 months, with this year growth rate of 63.54%, compared to 28.00% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -137.69% over the past 5 years.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders own 17.54% of the company shares, while shares held by institutions stand at 77.16% with a share float percentage of 93.57%. Investors are also buoyed by the number of investors in a company, with Taysha Gene Therapies Inc having a total of 156.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 21.21 million shares worth more than $47.51 million. As of 2024-06-30, FMR LLC held 9.1722% of shares outstanding.
The other major institutional holder is RTW INVESTMENTS, LP, with the holding of over 18.8 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.11 million and represent 8.1299% of shares outstanding.
